{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:34:21Z","timestamp":1789731261718,"version":"4.0.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012415","name":"Biomedical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012415","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001469","name":"Singapore General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Carbapenem-resistant <jats:italic>Klebsiella pneumoniae<\/jats:italic> (CRKP) is becoming increasingly problematic due to the limited effectiveness of new antimicrobials or other factors such as treatment cost. Thus, combination therapy remains a suitable treatment option. We aimed to evaluate the <jats:italic>in vitro<\/jats:italic> bactericidal activity of various antibiotic combinations against CRKP with different carbapenemase genotypes and sequence types (STs). Thirty-seven CRKP with various STs and carbapenemases were exposed to 11 antibiotic combinations (polymyxin B or tigecycline in combination with \u03b2-lactams including aztreonam, cefepime, piperacillin\/tazobactam, doripenem, meropenem, and polymyxin B with tigecycline) in static time-kill studies (TKS) using clinically achievable concentrations. Out of the 407 isolate-combination pairs, only 146 (35.8%) were bactericidal (\u22653 log<jats:sub>10<\/jats:sub>CFU\/mL decrease from initial inoculum). Polymyxin B in combination with doripenem, meropenem, or cefepime was the most active, each demonstrating bactericidal activity in 27, 24, and 24 out of 37 isolates, respectively. Tigecycline in combination with \u03b2-lactams was rarely bactericidal. Aside from the lower frequency of bactericidal activity in the dual-carbapenemase producers, there was no apparent difference in combination activity among the strains with other carbapenemase types. In addition, bactericidal combinations were varied even in strains with similar STs, carbapenemases, and other genomic characteristics. Our findings demonstrate that the bactericidal activity of antibiotic combinations is highly strain-specific likely owing to the complex interplay of carbapenem-resistance mechanisms, i.e., carbapenemase genotype alone cannot predict <jats:italic>in vitro<\/jats:italic> bactericidal activity. The availability of WGS information can help rationalize the activity of certain combinations. Further studies should explore the use of genomic markers with phenotypic information to predict combination activity.<\/jats:p>","DOI":"10.3389\/fmicb.2021.779988","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T14:16:18Z","timestamp":1639491378000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["In vitro Bactericidal Activities of Combination Antibiotic Therapies Against Carbapenem-Resistant Klebsiella pneumoniae With Different Carbapenemases and Sequence Types"],"prefix":"10.3389","volume":"12","author":[{"given":"Jocelyn Qi-Min","family":"Teo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazira","family":"Fauzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayden Jun-Yuan","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Hui","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon Jing-Yi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tze Peng","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiying","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Yi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurhayati","family":"Mohamed Yusoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Heng-Chiak","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuan Tong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick Twee-Hee","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Lay-Hoon","family":"Kwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s15010-019-01274-w","article-title":"Antagonistic effect between tigecycline and meropenem: successful management of KPC-producing Klebsiella pneumoniae infection.","volume":"47","author":"Bi","year":"2019","journal-title":"Infection"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1128\/AAC.01420-10","article-title":"Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae.","volume":"55","author":"Bulik","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","article-title":"Interplay between beta-lactamases and new beta-lactamase inhibitors.","volume":"17","author":"Bush","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1128\/AAC.03064-15","article-title":"Clinical Efficacy of polymyxin monotherapy versus nonvalidated polymyxin combination therapy versus validated polymyxin combination therapy in extensively drug-resistant gram-negative Bacillus infections.","volume":"60","author":"Cai","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.1128\/AAC.00270-16","article-title":"In vitro activity of polymyxin B in combination with various antibiotics against extensively drug-resistant Enterobacter cloacae with decreased susceptibility to polymyxin B.","volume":"60","author":"Cai","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e01509","DOI":"10.1128\/AAC.01509-16","article-title":"Evaluating polymyxin B-based combinations against carbapenem-resistant Escherichia coli in time-kill studies and in a hollow-fiber infection model.","volume":"61","author":"Cai","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jinf.2014.10.001","article-title":"Polymyxin B with dual carbapenem combination therapy against carbapenemase-producing Klebsiella pneumoniae.","volume":"70","author":"Chua","year":"2015","journal-title":"J Infect"},{"key":"B8","year":"1999","journal-title":"Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. CLSI document M26-A."},{"key":"B9","year":"2020","journal-title":"Performance Standards for Antimicrobial Susceptibility Testing CLSI Supplement M100"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/medsci6010001","article-title":"Carbapenem resistance: a review.","volume":"6","author":"Codjoe","year":"2017","journal-title":"Med Sci (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.1128\/AAC.01064-12","article-title":"The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic\/pharmacodynamic model.","volume":"56","author":"Deris","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cmi.2019.11.001","article-title":"Advances in the therapy of bacterial bloodstream infections.","volume":"26","author":"Giannella","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"B13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/08998280.2006.11928154","article-title":"Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics.","volume":"19","author":"Greer","year":"2006","journal-title":"Proc. (Bayl Univ Med Cent)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1128\/AAC.00670-10","article-title":"Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model.","volume":"55","author":"Hilliard","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"9654","DOI":"10.3390\/ijms16059654","article-title":"Structural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistance.","volume":"16","author":"Jeon","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1128\/AAC.06364-11","article-title":"The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae.","volume":"56","author":"Jernigan","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2147\/IDR.S172137","article-title":"Synergy effect of meropenem-based combinations against Acinetobacter baumannii: a systematic review and meta-analysis.","volume":"11","author":"Jiang","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"B18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4021\/jocmr1220w","article-title":"Polymyxins and doripenem combination against KPC-producing Klebsiella pneumoniae.","volume":"5","author":"Lee","year":"2013","journal-title":"J. Clin. Med. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.ijantimicag.2016.09.014","article-title":"Synergistic combinations of polymyxins.","volume":"48","author":"Lenhard","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1128\/aac.03639-14","article-title":"In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.","volume":"59","author":"Lim","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/cid\/ciaa122","article-title":"Carbapenem-resistant enterobacterales, carbapenem resistant organisms, carbapenemase-producing enterobacterales, and carbapenemase-producing organisms: terminology past its \u201cSell-By Date\u201d in an era of new antibiotics and regional carbapenemase epidemiology.","volume":"71","author":"Livermore","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1874285801711010063","article-title":"Synergistic effect of colistin and rifampin against multidrug resistant Acinetobacter baumannii: a systematic review and meta-analysis.","volume":"11","author":"Mohammadi","year":"2017","journal-title":"Open Microbiol. J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1128\/AAC.02463-14","article-title":"Antagonism between bacteriostatic and bactericidal antibiotics is prevalent.","volume":"58","author":"Ocampo","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cmi.2015.09.014","article-title":"Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae.","volume":"22","author":"Oliva","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: past, present, and future.","volume":"55","author":"Papp-Wallace","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/jac\/dkv294","article-title":"In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae.","volume":"71","author":"Poirel","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijantimicag.2010.10.031","article-title":"Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.","volume":"37","author":"Pournaras","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile beta-lactamases.","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1128\/AAC.01004-09","article-title":"Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.","volume":"54","author":"Queenan","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1086\/655995","article-title":"Progress and challenges in implementing the research on ESKAPE pathogens.","author":"Rice","year":"2010","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.7164\/antibiotics.30.1087","article-title":"Disruption of the Escherichia coli outer membrane permeability barrier by immobilized polymyxin B.","volume":"30","author":"Rosenthal","year":"1977","journal-title":"J. Antibiot. (Tokyo)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106344","article-title":"Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.","volume":"57","author":"Scudeller","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1128\/AAC.03894-14","article-title":"Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.","volume":"59","author":"Shields","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/2042098616643708","article-title":"Safety of high-dose doripenem in adult patients with cystic fibrosis.","volume":"7","author":"Strawbridge","year":"2016","journal-title":"Ther. Adv. Drug Saf."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025288","article-title":"Polymyxin: alternative mechanisms of action and resistance.","volume":"6","author":"Trimble","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"S279","DOI":"10.1093\/clinids\/8.supplement_3.s279","article-title":"Phenotypic tolerance: the search for beta-lactam antibiotics that kill nongrowing bacteria.","author":"Tuomanen","year":"1986","journal-title":"Rev. Infect. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.cmi.2020.03.007","article-title":"Evaluation of polymyxin B in combination with 13 other antibiotics against carbapenemase-producing Klebsiella pneumoniae in time-lapse microscopy and time-kill experiments.","volume":"26","author":"Wistrand-Yuen","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"B38","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.1128\/AAC.01230-13","article-title":"Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems.","volume":"57","author":"Zusman","year":"2013","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.779988\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T14:16:22Z","timestamp":1639491382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.779988\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":38,"alternative-id":["10.3389\/fmicb.2021.779988"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2021.779988","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]},"article-number":"779988"}}